Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- MRK
- Price
- 79.06
- Stock movement down
- -0.23 (-0.29%)
- Company name
- Merck & Company Inc
- Exchange
- (NYSE ,
- Currency
- USD )
- Sector
- Healthcare >Drug Manufacturers - General
- Market cap
- 197.47B
- Ent value
- 255.85B
- Price/Sales
- 3.12
- Price/Book
- 4.43
- Div yield
- 4.10%
- Div growth
- 9.30%
- Growth years
- 10
- FCF payout
- 65.23%
- Trailing P/E
- 16.26
- Forward P/E
- 8.23
- PEG
- 2.60
- EPS growth
- -42.71%
- 1 year return
- -37.99%
- 3 year return
- -2.19%
- 5 year return
- 2.30%
- 10 year return
- 3.66%
Last updated: 2025-08-27
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
Dividend yield - 5y
Loading...
Dividend yield data
| Dividend per share | 3.24 |
| Dividend yield | 4.10% |
| Payout frequency | Quarterly |
| Maximum yield | 4.41% |
| Average yield | 3.07% |
| Minimum yield | 2.32% |
| Discount to avg yield | 25.03% |
| Upside potential | 33.39% |
| Yield as % of max yield | 92.93% |
Yield distribution (inverse percentile) - 5y
Loading...
Yield distribution data
| Dividend yield | 4.10% |
| Current yield distribution | 2.38% |
| Yield at 100% (Min) | 2.32% |
| Yield at 90% | 2.51% |
| Yield at 80% | 2.65% |
| Yield at 50% (Median) | 3.08% |
| Yield at 20% | 3.45% |
| Yield at 10% | 3.60% |
| Yield at 0% (Max) | 4.41% |
Dividend per share
Loading...
Dividend per share data
| Years of growth | 10 years |
| CCC status | Dividend Contender |
| Dividend per share | 3.24 |
| Payout frequency | Quarterly |
| Ex-div date | 15 Sep 2025 |
| EPS (TTM) | 4.78 |
| EPS (1y forward) | 9.61 |
| EPS growth (5y) | -42.71% |
| EPS growth (5y forward) | 6.25% |
Dividend growth
Loading...
Please create a free account or log in to access this chart
Dividend growth data
| MRK | S&P500 | |
| DGR MR | 5.19% | -13.74% |
| DGR TTM | 5.19% | 6.60% |
| DGR 3 years | 7.77% | 5.24% |
| DGR 5 years | 9.30% | 5.40% |
| DGR 10 years | 6.02% | 7.07% |
| DGR 15 years | 4.88% | 6.12% |
| Time since last change announced | 292 days |
| EPS growth (5y) | -42.71% |
| EPS growth (5y forward) | 6.25% |
Payout ratio
Loading...
Please create a free account or log in to access this chart
Payout ratio data
| EPS coverage | FCF coverage | |
| TTM | 63.72% | 65.23% |
| Average | - | - |
| Forward | 33.73% | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 16.26 |
| Price to OCF | 10.81 |
| Price to FCF | 16.64 |
| Price to EBITDA | 13.79 |
| EV to EBITDA | 17.87 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 3.12 |
| Price to Book | 4.43 |
| EV to Sales | 4.05 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 2.50B |
| EPS (TTM) | 4.78 |
| FCF per share (TTM) | 4.67 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 63.22B |
| Gross profit (TTM) | 47.97B |
| Operating income (TTM) | 15.71B |
| Net income (TTM) | 12.15B |
| EPS (TTM) | 4.78 |
| EPS (1y forward) | 9.61 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 75.87% |
| Operating margin (TTM) | 24.86% |
| Profit margin (TTM) | 19.22% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 14.59B |
| Net receivables | 11.38B |
| Total current assets | 40.36B |
| Goodwill | 21.70B |
| Intangible assets | 17.01B |
| Property, plant and equipment | 42.52B |
| Total assets | 117.53B |
| Accounts payable | 3.59B |
| Short/Current long term debt | 38.13B |
| Total current liabilities | 29.59B |
| Total liabilities | 72.97B |
| Shareholder's equity | 44.56B |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 18.26B |
| Capital expenditures (TTM) | 3.42B |
| Free cash flow (TTM) | 11.87B |
| Dividends paid (TTM) | 7.74B |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 27.26% |
| Return on Assets | 10.34% |
| Return on Invested Capital | 14.69% |
| Cash Return on Invested Capital | 14.35% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 79.25 |
| Daily high | 79.92 |
| Daily low | 78.60 |
| Daily Volume | 34.1M |
| All-time high | 132.96 |
| 1y analyst estimate | 100.41 |
| Beta | 0.39 |
| EPS (TTM) | 4.78 |
| Dividend per share | 3.24 |
| Ex-div date | 15 Sep 2025 |
| Next earnings date | 30 Oct 2025 |
Downside potential
Loading...
Downside potential data
| MRK | S&P500 | |
| Current price drop from All-time high | -40.54% | -3.04% |
| Highest price drop | -76.62% | -56.47% |
| Date of highest drop | 9 Mar 2009 | 9 Mar 2009 |
| Avg drop from high | -30.64% | -11.04% |
| Avg time to new high | 33 days | 12 days |
| Max time to new high | 4793 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
197.47B
Marketcap category
Large-cap
Description
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions for animal identification, monitoring and traceability; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. The company has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. It has a collaboration agreement with Antengene Corporation Limited to evaluate the combination of ATG-022, a CLDN18.2-targeting antibody-drug conjugate, and ant
Employees
73000
Website
Investor relations
SEC filings
CEO
Kenneth Frazier
Country
USA
City
Kenilworth
Stock type
Common stock
CCC status
Dividend Contender
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page